Drug
Nedosiran clinical trials
Also written DCR-PHXC.
Keep track of what changes. Save the nedosiran studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (5) · Novo Nordisk A/S (1)
Studies
Open first, then newest update. How each study uses nedosiran is read from its arms, and is right about nine times in ten.
Testing it · 6
- Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDRecruitingPhase 2Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT04580420Written as DCR-PHXC
- Long Term Extension Study in Patients With Primary HyperoxaluriaActive, not recruitingPhase 3Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT04042402Written as DCR-PHXC
- Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal FunctionCompletedPhase 2Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT05001269Written as nedosiran
- Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary HyperoxaluriaCompletedPhase 1Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT03392896Written as DCR-PHXC
- Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 PatientsCompletedPhase 1Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT04555486Written as DCR-PHXC
- A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2CompletedPhase 2Novo Nordisk A/SNCT03847909Written as DCR-PHXC
Codes
What other systems call nedosiran · ClinicalTrials.gg INT001939
- MeSH (NLM) C000723113nedosiranConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 13U9R5J3WLNEDOSIRANConfirmed FDA, Wikidata
- Wikidata Q123420884nedosiranConfirmed FDA, Wikidata
- NCI Thesaurus C175828NedosiranOne source FDA
- DrugBank DB17635One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723113 | nedosiran | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 13U9R5J3WL | NEDOSIRAN | Confirmed FDA, Wikidata |
| Wikidata | Q123420884 | nedosiran | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175828 | Nedosiran | One source FDA |
| DrugBank | DB17635 | — | One source Wikidata |
Also registered as nedosiran sodium (UNII EGR9KYM536).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.